Home › with Excess of Blasts Refractory Anemia › North Carolina
with Excess of Blasts Refractory Anemia clinical trials in North Carolina
3 studies for with Excess of Blasts Refractory Anemia are looking for participants at sites in North Carolina.
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Duke University, Durham
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Apr 30, 2026 · NCT04256317A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- University of North Carolina, Chapel Hill
RecruitingPhase 2
Ages 18 to 66 · All sexes · Updated Mar 17, 2026 · NCT06859424Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
- Novant Health Cancer Institute, Charlotte
- Novant Health Cancer Institute, Winston-Salem
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Dec 10, 2025 · NCT06680752From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.